{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-048552","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2026-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.135378+00:00","generated_at":"2026-05-15T04:11:04.282686+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Altimmune raises ~$211M in public offering to fund MASH Phase 3 trial","bullets":["Offered 64.25M common shares at $3.00/share and pre-funded warrants for up to 10.75M shares.","Net proceeds of ~$211.2M after underwriting discounts and expenses; offering closed April 24, 2026.","Proceeds to fund pemvidutide Phase 3 MASH trial and pre-commercial activities.","Common stock warrants exercisable at $3.00/share for 5 years or 45 days after Phase 3 data announcement.","Warrants not listed on Nasdaq; beneficial ownership limits of 4.99% or 9.99% apply."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-048552","json":"https://secwatch.observer/filing/0001104659-26-048552.json","markdown":"https://secwatch.observer/filing/0001104659-26-048552.md","text":"https://secwatch.observer/filing/0001104659-26-048552.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/0001104659-26-048552-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/tm2612493d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:11:04.282686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a0533c74eb6df3b88485d25967a150807282e774","claim":"Altimmune, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters valued at approximately $211.2 million (effective 2026-04-22).","evidence_excerpt":"On April 22, 2026, Altimmune, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell (i) 64,250,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and accompanying common stock warrants to purchase shares of Common Stock (the “ Common Stock Warrants ”), to the Underwriters at a public offering price of $3.00 per share and (ii) in lieu of Common Stock to certain investors that so choose, pre-funded warrants (the “ Pre-Funded Warrants ” and together with the Common Stock Warrants, the “ Warrants ”) to purchase up to 10,750,000 shares of Common Stock to the Underwriters at a public offering price of $2.999 per Pre-Funded Warrant (the “ Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/0001104659-26-048552-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001193125-26-251791","ticker":"KRMN","company_name":"Karman Holdings Inc.","filed_at":"2026-06-01T21:28:29+00:00","headline":"Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds","event_type":"other_material","sec_items":["1.01","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251791","json":"https://secwatch.observer/filing/0001193125-26-251791.json","markdown":"https://secwatch.observer/filing/0001193125-26-251791.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/d117104d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 22, 2026, Altimmune, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell (i) 64,250,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and accompanying common stock warrants to purchase shares of Common Stock (the “ Common Stock Warrants ”), to the Underwriters at a public offering price of $3.00 per share and (ii) in lieu of Common Stock to certain investors that so choose, pre-funded warrants (the “ Pre-Funded Warrants ” and together with the Common Stock Warrants, the “ Warrants ”) to purchase up to 10,750,000 shares of Common Stock to the Underwriters at a public offering price of $2.999 per Pre-Funded Warrant (the “ Offering ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/0001104659-26-048552-index.htm","comparable_excerpt":"On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm"}},{"accession":"0001193125-26-251789","ticker":"GIPR","company_name":"GENERATION INCOME PROPERTIES, INC.","filed_at":"2026-06-01T21:27:59+00:00","headline":"Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit","event_type":"other_material","sec_items":["1.01","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251789","json":"https://secwatch.observer/filing/0001193125-26-251789.json","markdown":"https://secwatch.observer/filing/0001193125-26-251789.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/0001193125-26-251789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/gipr-20260528.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 22, 2026, Altimmune, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell (i) 64,250,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and accompanying common stock warrants to purchase shares of Common Stock (the “ Common Stock Warrants ”), to the Underwriters at a public offering price of $3.00 per share and (ii) in lieu of Common Stock to certain investors that so choose, pre-funded warrants (the “ Pre-Funded Warrants ” and together with the Common Stock Warrants, the “ Warrants ”) to purchase up to 10,750,000 shares of Common Stock to the Underwriters at a public offering price of $2.999 per Pre-Funded Warrant (the “ Offering ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/0001104659-26-048552-index.htm","comparable_excerpt":"In connection with the Offering, on May 28, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC, as placement agent","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/0001193125-26-251789-index.htm"}},{"accession":"0001213900-26-063576","ticker":"LOKV","company_name":"Live Oak Acquisition Corp. V","filed_at":"2026-06-01T21:00:23+00:00","headline":"Live Oak enters Forward Purchase Agreement to back Teamshares merger, up to 4M shares at ~$10.54","event_type":"other_material","sec_items":["1.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063576","json":"https://secwatch.observer/filing/0001213900-26-063576.json","markdown":"https://secwatch.observer/filing/0001213900-26-063576.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2048951/000121390026063576/0001213900-26-063576-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2048951/000121390026063576/ea0292781-8k425_liveoak5.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 22, 2026, Altimmune, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell (i) 64,250,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and accompanying common stock warrants to purchase shares of Common Stock (the “ Common Stock Warrants ”), to the Underwriters at a public offering price of $3.00 per share and (ii) in lieu of Common Stock to certain investors that so choose, pre-funded warrants (the “ Pre-Funded Warrants ” and together with the Common Stock Warrants, the “ Warrants ”) to purchase up to 10,750,000 shares of Common Stock to the Underwriters at a public offering price of $2.999 per Pre-Funded Warrant (the “ Offering ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/0001104659-26-048552-index.htm","comparable_excerpt":"On June 1, 2026, Live Oak Acquisition Corp. V, a Cayman Island exempted company (\" Live Oak \"), and HB Strategies LLC (\" Seller \" or \" FPA Investor \") entered into an agreement (the \" Forward Purchase Agreement \") for an OTC Prepaid Share Forward Transaction-Optional Early Termination (the \" Forward Purchase Transaction \") in connection with Live Oak’s proposed initial business combination (the \" Business Combination \") with Teamshares Inc., a Delaware corporation (\" Teamshares \" and the surviving public company following consummation of the Business Combination, the \" Combined Company \"), which is the subject of the previously-disclosed Agreement and Plan of Merger entered into by Live Oak and Teamshares as of November 14, 2025 (as amended as of April 1, 2026, and as may be further amended or supplemented from time to time, the \" Merger Agreement \").","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2048951/000121390026063576/0001213900-26-063576-index.htm"}},{"accession":"0001213900-26-063565","ticker":"AIB","company_name":"BlockchAIn Digital Infrastructure, Inc.","filed_at":"2026-06-01T20:57:13+00:00","headline":"Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063565","json":"https://secwatch.observer/filing/0001213900-26-063565.json","markdown":"https://secwatch.observer/filing/0001213900-26-063565.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/0001213900-26-063565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/ea0292328-8k_blockchain.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 22, 2026, Altimmune, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell (i) 64,250,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and accompanying common stock warrants to purchase shares of Common Stock (the “ Common Stock Warrants ”), to the Underwriters at a public offering price of $3.00 per share and (ii) in lieu of Common Stock to certain investors that so choose, pre-funded warrants (the “ Pre-Funded Warrants ” and together with the Common Stock Warrants, the “ Warrants ”) to purchase up to 10,750,000 shares of Common Stock to the Underwriters at a public offering price of $2.999 per Pre-Funded Warrant (the “ Offering ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/0001104659-26-048552-index.htm","comparable_excerpt":"On May 27, 2026, One Blockchain, LLC, a subsidiary of BlockchAIn Digital Infrastructure, Inc. (the “Company”) entered into a 15-year Electric Service Agreement (“Electric Service Agreement”) with a local utility provider (the “Utility Company”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/0001213900-26-063565-index.htm"}},{"accession":"0001379785-26-000024","ticker":"BBDC","company_name":"Barings BDC, Inc.","filed_at":"2026-06-01T20:15:45+00:00","headline":"Barings BDC receives $67M cash from adviser, enters new $11M credit support for Sierra legacy investments","event_type":"other_material","sec_items":["1.01","1.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001379785-26-000024","json":"https://secwatch.observer/filing/0001379785-26-000024.json","markdown":"https://secwatch.observer/filing/0001379785-26-000024.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1379785/000137978526000024/0001379785-26-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1379785/000137978526000024/bbdc-20260529.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 22, 2026, Altimmune, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell (i) 64,250,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and accompanying common stock warrants to purchase shares of Common Stock (the “ Common Stock Warrants ”), to the Underwriters at a public offering price of $3.00 per share and (ii) in lieu of Common Stock to certain investors that so choose, pre-funded warrants (the “ Pre-Funded Warrants ” and together with the Common Stock Warrants, the “ Warrants ”) to purchase up to 10,750,000 shares of Common Stock to the Underwriters at a public offering price of $2.999 per Pre-Funded Warrant (the “ Offering ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/0001104659-26-048552-index.htm","comparable_excerpt":"Barings BDC, Inc. (the “Company”) and Barings LLC (the “Adviser”) entered into a new Credit Support Agreement (the “New CSA”). The New CSA provides similar credit support as previously provided under the Prior CSA for the remaining unrealized investments in two portfolio companies previously covered by the Prior CSA in an amount equal to the $10,994,928 fair value of such investments as of May 29, 2026 (the “Remaining Obligation”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1379785/000137978526000024/0001379785-26-000024-index.htm"}},{"accession":"0001683168-26-004423","ticker":"CITR","company_name":"CitroTech Inc.","filed_at":"2026-06-01T20:15:28+00:00","headline":"CitroTech exchanges all Series A Preferred for Series C Convertible; BoltRock gets board rights","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004423","json":"https://secwatch.observer/filing/0001683168-26-004423.json","markdown":"https://secwatch.observer/filing/0001683168-26-004423.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/894556/000168316826004423/0001683168-26-004423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894556/000168316826004423/citro_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 22, 2026, Altimmune, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell (i) 64,250,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and accompanying common stock warrants to purchase shares of Common Stock (the “ Common Stock Warrants ”), to the Underwriters at a public offering price of $3.00 per share and (ii) in lieu of Common Stock to certain investors that so choose, pre-funded warrants (the “ Pre-Funded Warrants ” and together with the Common Stock Warrants, the “ Warrants ”) to purchase up to 10,750,000 shares of Common Stock to the Underwriters at a public offering price of $2.999 per Pre-Funded Warrant (the “ Offering ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/0001104659-26-048552-index.htm","comparable_excerpt":"On May 28, 2026, CitroTech Inc., a Wyoming corporation (the “Company”), entered into Stock Exchange and Stockholders Agreements (the “Exchange Agreements”) with the holders (the “Holders”) of the Company’s outstanding Series A Preferred Stock","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/894556/000168316826004423/0001683168-26-004423-index.htm"}},{"accession":"0001683168-26-004424","ticker":"LTRX","company_name":"LANTRONIX INC","filed_at":"2026-06-01T20:15:28+00:00","headline":"Lantronix prices $30M common stock offering at $7.20/share; net proceeds ~$32.3M","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004424","json":"https://secwatch.observer/filing/0001683168-26-004424.json","markdown":"https://secwatch.observer/filing/0001683168-26-004424.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1114925/000168316826004424/0001683168-26-004424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1114925/000168316826004424/lantronix_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 22, 2026, Altimmune, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell (i) 64,250,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and accompanying common stock warrants to purchase shares of Common Stock (the “ Common Stock Warrants ”), to the Underwriters at a public offering price of $3.00 per share and (ii) in lieu of Common Stock to certain investors that so choose, pre-funded warrants (the “ Pre-Funded Warrants ” and together with the Common Stock Warrants, the “ Warrants ”) to purchase up to 10,750,000 shares of Common Stock to the Underwriters at a public offering price of $2.999 per Pre-Funded Warrant (the “ Offering ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/0001104659-26-048552-index.htm","comparable_excerpt":"On May 29, 2026, Lantronix, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Needham & Company, LLC and Canaccord Genuity LLC, as underwriters (together, the “Underwriters”), pursuant to which the Company agreed to sell, and the Underwriters agreed to purchase, 4,166,667 shares (the “Firm Shares”) of the Company’s common stock","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1114925/000168316826004424/0001683168-26-004424-index.htm"}},{"accession":"0001493152-26-026603","ticker":"PUBC","company_name":"Purebase Corp","filed_at":"2026-06-01T19:42:27+00:00","headline":"Purebase to receive 20% of net proceeds from CoreTer mining deal; waives corporate opportunities","event_type":"other_material","sec_items":["1.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026603","json":"https://secwatch.observer/filing/0001493152-26-026603.json","markdown":"https://secwatch.observer/filing/0001493152-26-026603.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1575858/000149315226026603/0001493152-26-026603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1575858/000149315226026603/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 22, 2026, Altimmune, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell (i) 64,250,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and accompanying common stock warrants to purchase shares of Common Stock (the “ Common Stock Warrants ”), to the Underwriters at a public offering price of $3.00 per share and (ii) in lieu of Common Stock to certain investors that so choose, pre-funded warrants (the “ Pre-Funded Warrants ” and together with the Common Stock Warrants, the “ Warrants ”) to purchase up to 10,750,000 shares of Common Stock to the Underwriters at a public offering price of $2.999 per Pre-Funded Warrant (the “ Offering ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/0001104659-26-048552-index.htm","comparable_excerpt":"On May 26, 2026, Purebase Corporation (the “Company”) entered into a binding Memorandum of Understanding (the “MOU”) with CoreTer LLC, a Nevada limited liability company (“CoreTer”), pursuant to which the Company will be entitled to 20% of the net proceeds received by CoreTer under an Exclusive Mining Option and Development Agreement, dated March 19, 2026, between CoreTer and Dexter Mining LLC.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1575858/000149315226026603/0001493152-26-026603-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}